Prati
Marc-Oliver Grimm
Marc-Oliver Grimm
Nepoznata afilijacija
Potvrđena adresa e-pošte na med.uni-jena.de
Naslov
Citirano
Citirano
Godina
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
RJ Motzer, NM Tannir, DF McDermott, OA Frontera, B Melichar, ...
New England Journal of Medicine, 2018
27632018
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
P Sharma, M Retz, A Siefker-Radtke, A Baron, A Necchi, J Bedke, ...
The lancet oncology 18 (3), 312-322, 2017
13242017
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised …
RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ...
The Lancet Oncology 20 (10), 1370-1385, 2019
4432019
Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study
MO Grimm, C Steinhoff, X Simon, P Spiegelhalder, R Ackermann, ...
The Journal of urology 170 (2), 433-437, 2003
4192003
Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study
D Jocham, F Witjes, S Wagner, B Zeylemaker, J van MOORSELAAR, ...
The Journal of urology 174 (3), 862-866, 2005
3322005
The contemporary concept of significant versus insignificant prostate cancer
G Ploussard, JI Epstein, R Montironi, PR Carroll, M Wirth, MO Grimm, ...
European urology 60 (2), 291-303, 2011
3252011
A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma
C Wülfing, JPH Machiels, DJ Richel, MO Grimm, U Treiber, MR De Groot, ...
Cancer 115 (13), 2881-2890, 2009
2422009
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions
JC Hassel, L Heinzerling, J Aberle, O Bähr, TK Eigentler, MO Grimm, ...
Cancer treatment reviews 57, 36-49, 2017
2402017
A multicenter randomized noninferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of …
JA Thomas, A Tubaro, N Barber, F d’Ancona, G Muir, U Witzsch, ...
European urology 69 (1), 94-102, 2016
2322016
180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of …
A Bachmann, A Tubaro, N Barber, F d’Ancona, G Muir, U Witzsch, ...
European urology 65 (5), 931-942, 2014
2112014
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
TK Choueiri, RJ Motzer, BI Rini, J Haanen, MT Campbell, B Venugopal, ...
Annals of Oncology 31 (8), 1030-1039, 2020
2022020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, ...
ESMO open 5 (6), e001079, 2020
1902020
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised …
DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ...
The Lancet 390 (10109), 2266-2277, 2017
1902017
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
D Cella, V Grünwald, B Escudier, HJ Hammers, S George, P Nathan, ...
The Lancet Oncology 20 (2), 297-310, 2019
1692019
Assessment of PI-RADS v2 for the detection of prostate cancer
M Kasel-Seibert, T Lehmann, R Aschenbach, FV Guettler, M Abubrig, ...
European journal of radiology 85 (4), 726-731, 2016
1612016
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
1562020
A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign …
A Bachmann, A Tubaro, N Barber, F d’Ancona, G Muir, U Witzsch, ...
The Journal of urology 193 (2), 570-578, 2015
1362015
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05)
J Lehmann, H Suttmann, P Albers, B Volkmer, JE Gschwend, G Fechner, ...
European urology 55 (6), 1293-1299, 2009
1292009
Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles
O Modlich, HB Prisack, G Pitschke, U Ramp, R Ackermann, H Bojar, ...
Clinical cancer research 10 (10), 3410-3421, 2004
1272004
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a …
RJ Motzer, B Escudier, DF McDermott, OA Frontera, B Melichar, T Powles, ...
Journal for immunotherapy of cancer 8 (2), 2020
1192020
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20